Multimodal survival prediction in advanced pancreatic cancer using machine learning

ESMO Open. 2022 Oct;7(5):100555. doi: 10.1016/j.esmoop.2022.100555. Epub 2022 Aug 18.

Abstract

Background: Existing risk scores appear insufficient to assess the individual survival risk of patients with advanced pancreatic ductal adenocarcinoma (PDAC) and do not take advantage of the variety of parameters that are collected during clinical care.

Methods: In this retrospective study, we built a random survival forest model from clinical data of 203 patients with advanced PDAC. The parameters were assessed before initiation of systemic treatment and included age, CA19-9, C-reactive protein, metastatic status, neutrophil-to-lymphocyte ratio and total serum protein level. Separate models including imaging and molecular parameters were built for subgroups.

Results: Over the entire cohort, a model based on clinical parameters achieved a c-index of 0.71. Our approach outperformed the American Joint Committee on Cancer (AJCC) staging system and the modified Glasgow Prognostic Score (mGPS) in the identification of high- and low-risk subgroups. Inclusion of the KRAS p.G12D mutational status could further improve the prediction, whereas radiomics data of the primary tumor only showed little benefit. In an external validation cohort of PDAC patients with liver metastases, our model achieved a c-index of 0.67 (mGPS: 0.59).

Conclusions: The combination of multimodal data and machine-learning algorithms holds potential for personalized prognostication in advanced PDAC already at diagnosis.

Keywords: computed tomography; genetics; machine learning; pancreatic cancer; prognosis; survival analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / pathology
  • C-Reactive Protein
  • CA-19-9 Antigen
  • Humans
  • Machine Learning
  • Neoplasm Staging
  • Pancreatic Neoplasms* / diagnosis
  • Prognosis
  • Proto-Oncogene Proteins p21(ras)
  • Retrospective Studies

Substances

  • C-Reactive Protein
  • CA-19-9 Antigen
  • Proto-Oncogene Proteins p21(ras)